Daxor Corporation announced the appointment of Lisa Quartley as its first SVP, Marketing and Commercial Development. Ms. Quartley will be leading a newly focused and reinvigorated commercialization effort for the company's unique diagnostic technology with the goal of making direct blood volume measurement a standard of care. Within the past five years she has led consultancy-side strategic efforts for key brands at Genentech, Novartis, Bristol-Myers Squibb, and Eisai.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.79 USD | +0.06% | +3.41% | -8.44% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.44% | 44.5M | |
+5.79% | 13.02B | |
+17.03% | 9.99B | |
+1.80% | 5.69B | |
-1.17% | 5.47B | |
+30.45% | 5.2B | |
+5.13% | 5.16B | |
+24.44% | 4.76B | |
+3.73% | 4B | |
-2.89% | 3.83B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Appoints Lisa Quartley as its First SVP, Marketing and Commercial Development